Skip to main content
SpringerLink
Log in

Comprehensive needs, social support, and disease perception in lung cancer patients treated with immune checkpoint inhibitors: a cross-sectional study

  • Research
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to investigate the comprehensive needs of lung cancer patients treated with immune checkpoint inhibitors and to explore the relationships between comprehensive needs and social support and disease perception, moreover, to analyse associated factors of comprehensive needs.

Methods

The study was conducted in a teaching hospital in Jiaxing Province, China. A total of 141 patients with lung cancer completed a battery of self-report questionnaires, including the Comprehensive Needs Assessment Tool in Cancer for Patients (CNAT), Social Supportive Rating Scale (SSRS), Brief Illness Perception Questionnaire (BIPQ), and demographic and clinical characteristics questionnaire.

Results

The level of comprehensive needs was highest in the domain “medical demand” (42.17 ± 26.57), and the item with the highest level of comprehensive needs was “I need information about the financial support for my medical expenses” (2.00 ± 1.07). Statistically significant correlations were identified between the comprehensive needs score, social support, and disease perception. The multiple regression analysis showed that immunotherapy course, whether irAEs occur, social support, and disease perception were factors influencing patients’ comprehensive needs.

Conclusions

The most prevalent needs in lung cancer patients were found in the “medical needs” domain. Additionally, immunotherapy course, whether irAEs occur, disease perception, and social support were associated with comprehensive needs among lung cancer patients. It is essential to combine the associated factors to accurately evaluate patient needs. We should pay more attention to proposing the comprehensive measures for these patients and providing more individualized supportive care during the lengthy treatment period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Data for this study are available. Data can be provided if needed.

References

  1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

    Article  PubMed  Google Scholar 

  2. Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132

    Article  PubMed  Google Scholar 

  3. Shi JF, Wang L, Wu N et al (2019) Clinical characteristics and medical-service utilization of lung cancer in China, 2005–2014: overall-design and results from a multicenter retrospective epidemiologicsurvey. Lung Cancer 128:91–100

    Article  PubMed  Google Scholar 

  4. Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cao M, Chen W (2019) Epidemiology of lung cancer in China. Thorac Cancer 10(1):3–7

    Article  PubMed  Google Scholar 

  6. Hirsch L, Zitvogel L, Eggermont A, Marabelle A (2019) PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br J Cancer 120(1):3–5

    Article  PubMed  Google Scholar 

  7. Hoos A (2016) Development of immune-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discovery 15(4):235–247

    Article  CAS  PubMed  Google Scholar 

  8. Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580

    Article  CAS  PubMed  Google Scholar 

  9. Sanmamed MF, Chen L (2018) A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175(2):313–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wrobel P, Ahmed S (2018) Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis 34(1):13–25

    Article  PubMed  Google Scholar 

  11. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fecher LA, Agarwala SS et al (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18(6):733–743

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wolchock JD, Neyns B et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164

    Article  Google Scholar 

  14. Hodi O’Day SJ et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dummer Weber JS, R, et al (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119(9):1675–1682

    Article  PubMed  Google Scholar 

  16. Institute of Medicine (US) (2008) Committee on psychosocial services to cancer patients/families in a community setting. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. Adler NE, Page AEK, editors. Washington (DC): National Academies Press (US)

  17. Newell S, Sanson-Fisher RW, Girgis A, Ackland S (1999) The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study. Eur J Cancer Care (Engl) 8(2):73–82

    Article  CAS  PubMed  Google Scholar 

  18. Ping Ni, Jingli C, Na L (2010) Sample size estimation for quantitative studies in nursing studies. Chin J Nurs 45(4):378–380

    Google Scholar 

  19. Shim EJ, Lee KS, Park JH et al (2011) Comprehensive needs assessment tool in cancer (CNAT): the development and validation. Support Care Cancer 19(12):1957–1968

    Article  PubMed  Google Scholar 

  20. Sun Z (2007) Medical statistics. People’s Medical Publishing House, Beijing

  21. Xiuying Gu, Zheng Rongshou, Xia Changfa et al (2019) The intereffect of life expectation and cancer morbidity and mortality in China: a population-based cluster analysis. Cancer 38(1):23–38

    Google Scholar 

  22. Shin DW, Park JH, Shim EJ et al (2011) The development of a comprehensive needs assessment tool for cancer-caregivers inpatient-care giver dyads. Psychooncology 20(12):1342–1352

    Article  PubMed  Google Scholar 

  23. Zhao X, Zhang L, Li C (2017) Sinicization and reliability and validity test of the comprehensive needs assessment scale of cancer patients. Chin J Nurs 52(1):34–39

    Google Scholar 

  24. Xiao Water Source (1994) Theoretical basis and research application of the Social Support Rating Scale. J Clin Psychiatry 4(2):98–100

    Google Scholar 

  25. Li W, Jing T (2012) Investigation and analysis of psychological problems and social support in patients and nursing intervention after radical surgery of breast cancer. Jilin Medical 33(13):2836–2838

    CAS  Google Scholar 

  26. Broadbent E, Petrie KJ, Main J et al (2006) The Brief Illness Perception Questionnaire. J Psychosom Res 60(6):631–637

    Article  PubMed  Google Scholar 

  27. Broadbent E, Wilkes C, Koschwanez H et al (2015) A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. Psychol Health 30(11):1361–1385

    Article  PubMed  Google Scholar 

  28. Zhang N, Fielding R, Soong I, Chan KK, Lee C, Ng A, Sze WK, Tsang J, Lee V, Lam WW (2017) Psychometric assessment of the Chinese version of the brief illness perception questionnaire in breast cancer survivors. PLoS One 12(3):e0174093

  29. Yaqi M, Huiping Li, Yajuan Y et al (2015) Credit validity test of the simplified version of the disease perception questionnaire in female breast cancer patients. J Nurs 22(24):11–14

    Google Scholar 

  30. McLouth LE, Nightingale CL, Levine BJ et al (2021) Unmet care needs and financial hardship in patients with metastatic non–small-cell lung cancer on immunotherapy or chemoimmunotherapy in clinical practice. JCO Oncol Pract 17(8):e1110–e1119

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sanders SL, Bantum EO et al (2010) Supportive care needs in patients with lung cancer. Psycho-Oncology 19:480–489

    Article  PubMed  Google Scholar 

  32. Sung MR, Patel MV, Djalalov S et al (2017) Evolution of symptom burden of advanced lung cancer over a decade. Clin Lung Cancer 18(3):274–280

    Article  PubMed  Google Scholar 

  33. Cochrane A, Woods S, Dunne S, Gallagher P (2022) Unmet supportive care needs associated with quality of life for people with lung cancer: a systematic review of the evidence 2007–2020. Eur J Cancer Care (Engl) 31(1):e13525

    Article  PubMed  Google Scholar 

  34. Cooper MR, Alrajhi AM, Durand CR (2018) Role of immune checkpoint inhibitors in small cell lung cancer. Am J Ther 25(3):e349–e356

    Article  PubMed  Google Scholar 

  35. Ugalde A, Aranda S, Krishnasamy M et al (2012) Unmet needs and distress in people with inoperable lung cancer at the commencement of treatment. Support Care Cancer 20(2):419–423

    Article  PubMed  Google Scholar 

  36. Al Achkar M, Marchand L, Thompson M et al (2020) Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study. BMJ Open 10(3):e032639

    Article  PubMed  PubMed Central  Google Scholar 

  37. Puts MTE, Papoutsis A, Springall E, Tourangeau AE (2012) A systematic review of unmet needs of newly diagnosed older cancer patients undergoing active cancer treatment. Support Care Cancer 20(7):1377–1394

    Article  CAS  PubMed  Google Scholar 

  38. Rotter J, Spencer JC, Wheeler SB (2019) Financial toxicity in advanced and metastatic cancer: overburdened and underprepared. J Oncol Pract 15(4):e300–e307

    Article  PubMed  PubMed Central  Google Scholar 

  39. de Moor JS, Dowling EC, Ekwueme DU et al (2017) Employment implications of informal cancer caregiving. J Cancer Surviv 11(1):48–57

    Article  PubMed  Google Scholar 

  40. Wan Y, Gao X, Mehta S et al (2013) Indirect costs associated with metastatic breast cancer. J Med Econ 16(10):1169–1178

    Article  PubMed  Google Scholar 

  41. Fong EJ, Cheah WL (2016) Unmet supportive care needs among breast cancer survivors of community-based support group in Kuching Sarawak. Int J Breast Cancer 2016:1–9

    Article  Google Scholar 

  42. Qin Yanli, Wang Fang (2020) Analysis on the supportive care needs and influencing factors of head and neck cancer patients. Dissertion, Chengdu University of Traditional Chinese Medicine, Sichuan

  43. Xu S, Liu Y (2018) Observation and nursing of immune-related adverse reactions in malignant tumor patients treated with procedural death receptor 1 antibody (PD-1). Nurs Refresh Mag 33(04):355–356

    Google Scholar 

  44. Weber JS, Yang JC, Atkins MB et al (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092–2099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhou X, Yao Z, Bai H et al (2021) Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol 22(9):1265–1274

    Article  CAS  PubMed  Google Scholar 

  46. Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(13):1270–1271

    Article  PubMed  Google Scholar 

  47. Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):1–28

    Article  PubMed  PubMed Central  Google Scholar 

  48. Rui W, Caihong Y, Tian Z et al (2021) The relation between spiritual needs and disease perception control, post-traumatic growth. Nursing Practice and Research 18(4):5

    Google Scholar 

  49. Lamkin DM, Lutgendorf SK, McGinn S et al (2008) Positive psychosocial factors and NKT cell sinovarian cance rpatients. BrainBehav Immun 22:65–73

    Article  CAS  Google Scholar 

  50. Lien CY, Lin HR, KuoI T et al (2009) Perceived uncertainty, social support and psychological adjustment in older patients with cancer being treated with surgery. JClinNurs 18:2311–2319

    Google Scholar 

  51. Lei C, Yuhong Li, Yanping Li, Qianyun W (2019) Investigation of 141 supportive care needs and social support. Anhui Medical Corporation 23(08):1559–1562

    Google Scholar 

  52. Chae BJ, Lee J, Lee SK et al (2019) Unmet needs and related factors of Korean breast cancer survivors: a multicenter, cross-sectional study. BMC Cancer 19(1):816–839

    Article  Google Scholar 

  53. Karatas T, Özen S, Kutlutürkan S (2017) Factor structure and psychometric proper ties of the Brief Illness Perception Questionnaire in Turkish cancer patients. Asia Pac J Oncol Nurs 4(1):77–83

    Article  PubMed  PubMed Central  Google Scholar 

  54. Luszczynska A, Pawlowska I, Cieslak R et al (2013) Social support and quality of life among lung cancer patients: a systematic review. Psychooncology 22:2160–8

    Article  PubMed  Google Scholar 

  55. Aiping Y, Xue B, Yaqiong L (2007) Impact of social support on the medical treatment behavior of cancer patients. Med Soc 20(8):42–44

    Google Scholar 

Download references

Acknowledgements

The authors thank all lung cancer patients who participated in this studies and all those who contributed to this study.

Funding

This study was supported by the Jiaxing City Science and Technology Program Project, number 2022AD10019.

Author information

Authors and Affiliations

  1. Department of Nursing, Medical College, Jiaxing College, No.899, Guangdome Road, Nanhu District, Jiaxing, Zhejiang Province, China

    Xiaoyan Luo, Lingru Guo, Li Zhou, Haiying Jiang & Ren-Shan Cui

  2. Department of Medical Oncology, The First Hospital of Jiaxing, South Zhonghuan Road, Jiaxing, 1882314001, Zhejiang Province, China

    Ningning Zhang

Authors
  1. Xiaoyan Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ningning Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingru Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haiying Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ren-Shan Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Xiao Yan Luo: conceptualization, methodology, data analysis, data collection, writing—original draft.

Ren Shan Cui: writing—review and editing, supervision, funding acquisition.

Ningning Zhang: provided the data collection site, data collection, questionnaire translation.

Lingru Guo and Zhou Li: language support, revising, and checked up the paper.

Haiying Jiang: reviewed and polished the revised paper.

Corresponding author

Correspondence to Ren-Shan Cui.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

It does not apply because the study is only a survey study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luo, X., Zhang, N., Guo, L. et al. Comprehensive needs, social support, and disease perception in lung cancer patients treated with immune checkpoint inhibitors: a cross-sectional study. Support Care Cancer 32, 166 (2024). https://doi.org/10.1007/s00520-024-08348-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00520-024-08348-y

Keywords

Search

Navigation